in attempts to target these agents to tumors. These latter modifications all involve covalent attachment to tyrosines, e-amino side chains of lysines, carboxyl side chains of aspartic and glutamic acids, or sulfhydryl groups generated by reduction of cystines. Although each of these applications has shown promise, none, as yet, has reached the point of proven clinical utility. Since so many of the diagnostic and therapeutic applications envisioned for monoclonal antibodies require coupling of antibodies to other substances, there is a need for methods of covalent modification that can be used on a broad spectrum of different antibodies with minimal effect on antigen binding properties. This paper will present a strategy for site-specific covalent modification of antibodies based upon attachment through the oligosaccharide moiety of the molecule. Because of the restricted localization of the glycosylation sites on immunoglobulins, such an approach offers the potential advantage of modification of the antibodies at a site distal to the antigen combining site (29). Data will be presented that first compares the effect of various techniques of monoclonal antibody modification on the antigenbinding homogeneity and affinity of the conjugate. Second, the comparative in vivo biodistribution and tumor localization of additional radiolabeled monoclonal antibodies will be presented using nude mice bearing subcutaneous tumor xenografts.
ity. In vivo biodistribution and nuclear-imaging experiments were also performed with a second monoclonal antibody and a tumor xenograft model. Antibodies modified on the oligosaccharides with either (i) a peptide labeled with iodine-125 or (ii) a diethylenetriaminepentaacetic acid chelate with indium-lll localize into target tumors more efficiently than the same antibody radiolabeled on either tyrosines or lysines. These in vivo results, when compared to those reported in the literature for conventionally modified antibodies, suggest that oligosaccharide modification of monoclonal antibodies is a preferred method of preparing conjugates.
The development of monoclonal antibody technology (1) has given new emphasis to the potential use of antibodies for targeting various substances to tumors in vivo. To this end, monoclonal antibodies have been developed for a number of human neoplasms, some of which have already been evaluated in patients (2) (3) (4) (5) . For in vivo diagnostic applications, antibodies typically are labeled with remitting isotopes for use in immunoscintigraphy. Labeling is achieved by coupling iodine-131 or iodine-123 to tyrosines (6) (7) (8) (9) (10) (11) (12) (13) (14) , by coupling indium-ill to chelators that are coupled to lysines (12, (15) (16) (17) (18) (19) , or by passively adsorbing technetium-99m (20) . For therapeutic applications, antibodies are sometimes used as unmodified proteins (2, 5) , but more commonly they are attached to isotopes (4, 21, 22) , toxins (23) , toxin fragments (24, 25) , or any one of a number of cytotoxic drugs (9, (26) (27) (28) in attempts to target these agents to tumors. These latter modifications all involve covalent attachment to tyrosines, e-amino side chains of lysines, carboxyl side chains of aspartic and glutamic acids, or sulfhydryl groups generated by reduction of cystines. Although each of these applications has shown promise, none, as yet, has reached the point of proven clinical utility.
Since so many of the diagnostic and therapeutic applications envisioned for monoclonal antibodies require coupling of antibodies to other substances, there is a need for methods of covalent modification that can be used on a broad spectrum of different antibodies with minimal effect on antigen binding properties. This paper will present a strategy for site-specific covalent modification of antibodies based upon attachment through the oligosaccharide moiety of the molecule. Because of the restricted localization of the glycosylation sites on immunoglobulins, such an approach offers the potential advantage of modification of the antibodies at a site distal to the antigen combining site (29) . Data will be presented that first compares the effect of various techniques of monoclonal antibody modification on the antigenbinding homogeneity and affinity of the conjugate. Second, the comparative in vivo biodistribution and tumor localization of additional radiolabeled monoclonal antibodies will be presented using nude mice bearing subcutaneous tumor xenografts.
MATERIALS AND METHODS
In Vitro Binding. The mouse monoclonal anti-phosphocholine IgM, HPCM2 (30) , was grown in BALB/c mice and purified from ascites by ammonium sulfate precipitation, followed by affinity chromatography (31) . The following conjugates of HPCM2 were prepared.
(i) For oligosaccharide attachments, the oligosaccharides moieties were oxidized to aldehydes by incubation in the dark with 10-30 mM NaIO4 in phosphate-buffered saline (0.15 M NaCl/0.01 M sodium phosphate) at pH 6.0 on ice for 1 hr. After passage through a Sephadex G-25 column equilibrated with phosphate-buffered saline at pH 6.0, oxidized antibody was incubated with a 270-fold molar excess of 1,6-diaminohexylethylenediaminedi-o-hydroxyphenylacetic acid (1,6-diaminohexyl-EDDHA) § for 1 hr at room temperature. Sodium cyanoborohydride (Aldrich) was added to a final concentration of 10 mM, and the solution was incubated for an additional 4 hr and then dialyzed at 4°C versus several changes of phosphate-buffered saline.
(ii) For aspartic/glutamic acid attachments, the antibody was incubated in 20 mM 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (Sigma) at pH 5.9 for 2 hr at room temperature. The 1,6-diaminohexyl-EDDHA was added to a final concentration of 10 mM, and the solution was incubated at room temperature for an additional 2 hr. Ten microliters of 1 M ethanolamine was added, and, after 1 hr the reaction mixture was dialyzed versus phosphate-buffered saline.
(iii) For lysine attachments, the scheme for aspartic/glutamic acid modification was used except that EDDHA (5 mM; Sigma) replaced the 1,6-diaminohexyl-EDDHA.
Abbreviations: EDDHA, ethylenediamine-di-o-hydroxyphenylacetic acid; DTPA, diethylenetriaminepentaacetic acid; MHC, major histocompatibility complex; T/B, tissue-to-blood ratio; RES, reticuloendothelial system. tPresent address: Department of Chemistry, California Polytechnic State University, San Luis Obispo, CA 93407. §The synthesis of these compounds will be published elsewhere.
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For all preparations, the average number of groups attached was five, as determined by the formation of the fluorescent EDDHA chelate with terbium (32) .
Affinities of the native anti-phosphocholine antibody and the conjugates for the ligand N-(2,4-dinitrophenyl)-paminophenylphosphocholine were measured by the technique of fluorescence quenching (33) as described elsewhere (34) .
In Vivo Biodistribution. The monoclonal antibody (R9.75) used for the in vivo biodistribution experiments is a rat IgG2c specific for a class I major histocompatibility complex (MHC) antigen of BN rats (35) . Ascites was produced in nude mice, and the antibody was purified by gradient elution from a protein A-Sepharose column (Pharmacia) (36) .
The control antibody was a mouse monoclonal IgG2b, designated KE2, specific for a human HLA determinant (a gift from Roger Kennett, University of Pennsylvania). Purity of all antibody preparations was confirmed by NaDodSO4/polyacrylamide gel electrophoresis (37) .
"2SI-abeled conjugates. R9.75 was labeled on endogenous tyrosines with Na'"I (Amersham) using the chloramine-T method (38) . Alternatively, the synthetic pentapeptide glycyltyrosylglycylglycylarginine, prepared by standard solidphase synthetic methods (39) , was radiolabeled at the tyrosine (38) with Nal25I before coupling to the oxidized oligosaccharides of R9.75 as described.
"'In-labeled diethylenetriaminepentaacetic acid (DTPA)-antibody conjugates. In brief, these conjugates were prepared in two ways.
(i) Oligosaccharide attachment. R9.75 or KE2 oligosaccharides were oxidized as described, and then the modified antibodies were incubated with either glycyltyrosyllysyl-DTPA or p-aminoaniline-DTPA. Incubation conditions were as described above, except that a 1000-fold molar excess of chelator was used. Two to five hundred micrograms of these antibodies in phosphate-buffered saline were radiolabeled with "'In (New England Nuclear). Radiolabeled antibodies were separated from free "'1In by elution through a Sepharose G-50 column. The specific activities ranged from 1 to 5 ,uCi/,ug (1 Ci = 37 GBq).
(ii) Lysine attachment. R9.75 was coupled to DTPA and incubated with "'1In as described (17 (34), this analysis assumes that each sample is composed of a homogeneous population of antigen-binding molecules. When this is the case, the data will fit a line with a slope of 1. In fact, the data for the unmodified monoclonal antibody and the oligosaccharide conjugate fit a line of such slope. In contrast, data for the other samples deviate significantly from such a line, which is evidence that these conjugates are composed of a mixture of antigen-binding molecules with different affinities. Furthermore, this analysis yields a value for the association constant of the antibody preparations that derives solely from the active antigen binding proportion in each preparation (34) . Compared to the unmodified antibody, the conjugates coupled directly on amino acid side chains had significantly lower affinities, while the oligosaccharide-coupled conjugate did not (Fig. 1) .
In Vivo Biodistribution. The in vivo localization of different conjugates of a monoclonal antibody, R9.75, was evaluated by injection into nude mice bearing BN lymphoma xenografts on their left flank. Normal nude mice were used as controls. Animals were dissected 24 or 48 hr after injection, and the organs were weighed and counted. The percentage of total injected dose per gram of tissue and tissue-to-blood ratios (T/B) were then calculated.
The first comparison was between R9.75 that was 1251_ labeled by direct iodination of tyrosines and R9.75 that was coupled through the oligosaccharides to a radioiodinated peptide. The preparations had equivalent in vitro cell-binding activities ( Table 1 ). The biodistribution data from dissection and organ counting of animals 24 hr after injection are shown in Table 1 . There was little nonspecific uptake of either conjugate into any organ of the control mice, but a comparison of the percentage of the total injected dose per organ in tumor-bearing animals demonstrates greater tumor localization in animals injected with the oligosaccharide-linked conjugate compared to the directly iodinated antibody.
The T/B ratios show that the directly labeled antibody did not localize well to the tumor at this time point.
The next comparison involved similar evaluation of the in vivo behavior of "'In-labeled R9.75. The first experiment was designed to compare standard modification chemistry (17), involving attachment of DTPA to lysines, with oligosaccharide modification by the method described above. The specific activities achieved after chelation to "'in were the same for both conjugates. BN tumor-bearing animals were imaged without background subtraction 24 hr after injection. Fig. 2 illustrates the results ofthis comparison. Fig. 2A shows the image obtained 24 hr after injection of the "'In-labeled oligosaccharide-modified antibody conjugate. Fig. 2B is a photograph showing the typical size of the xenograft at this time. Fig. 2C is the image seen with the nonselectively modified antibody. The oligosaccharide-modified antibody localized well into the tumor, while the nonselectively labeled conjugate localized mainly to the liver region.
"'1In-labeled oligosaccharide-modified R9.75 conjugates were further evaluated by imaging tumor-bearing mice 24, 48, and 72 hr after injection (Fig. 3 A-C) . Mice imaged at all these time points showed clear tumor localization. A number of control experiments were also performed. Fig. 3D is a typical 24-hr image of a normal mouse injected with this antibody conjugate, in which no discrete tissue localization is observed. 
DISCUSSION
This study was undertaken in order to compare, both in vitro and in vivo, site-specific covalent modification of monoclonal antibodies via their oligosaccharides with more conventional methods involving tyrosine, lysine, and aspartic/glutamic acid attachment. Chemical or enzymic oxidation of antibody oligosaccharides to aldehydes yields unique functional groups on the molecule, which can selectively react with compounds containing, for example, amines, hydrazines, hydrazides, and semicarbazides (41) (42) (43) . Since the sites of attachment of oligosaccharides to antibodies are specific and distal to the antibody-combining site (29) , selective coupling to aldehydes should yield more uniform antibody conjugates with unimpaired antigen-binding characteristics. In contrast, a common feature of covalent modification at tyrosines, lysines, or aspartic/glutamic acids is the lack of selectivity inherent in the methods used. Lack of selectivity in this context refers to the inability to control the coupling to a particular reactive amino acid at a specific location on the molecule. This leads to conjugates with a distribution of attachment sites, some ofwhich may be located at or near the antibody-combining site. The result could be weakened or lost antigen-binding activity for some proportion of the antibody conjugates, depending upon the degree to which the architecture of the combining site is perturbed, or access blocked, by covalent attachments. The in vitro binding data in Fig. 1 support the inferred advantage of covalent modification of monoclonal antibodies at the oligosaccharides over conventional methods; namely, that such conjugates retain the homogeneous antigen-binding properties and affinity of the unmodified protein. In contrast, conjugates of the same antibody prepared by coupling to lysines or to aspartic/glutamic acid residues have both reduced affinity and heterogeneous antigen-binding properties.
In vivo, the utility ofmonoclonal antibodies depends in part upon their homogeneous antigen-binding specificity. It was important, therefore, to determine if modification at the oligosaccharide yields covalent conjugates that express their immunological specificity better than conventional conjugates in vivo. The initial comparison involved biodistribution experiments in normal and tumor xenograft-bearing nude mice by using a monoclonal antibody modified with 125I either on endogenous tyrosines or coupled to a tyrosine-containing peptide, which was then site-specifically attached to oxidized oligosaccharides. After 24 hr (Table 1 ) the conjugate modified with 125I on the oligosaccharides localized in the tumor with a 18-fold greater efficiency than the corresponding conjugate modified nonselectively on tyrosines. This occurred in spite of comparable in vitro cell binding activities for the two preparations. This suggests that in vivo localization to small subcutaneous-tumors is a more stringent test of the immunological activity of an antibody conjugate than in vitro cell binding experiments. Both normal and tumor-bearing mice injected with the directly labeled antibody had poor retention of radioactivity after 24 hr. This is attributed to dehalogenation in the liver followed by loss of the 125I via excretion. Since the animals' thyroids were blocked by a large excess of free iodine in their drinking water, uptake of 1"5I at this site could not be evaluated. Strikingly, >80o of the conjugate ['25Iliodinated on the oligosaccharides was retained by the animals that received this preparation, perhaps suggesting that positioning the radiolabel on the oligosaccharides may shield it from dehalogenation.
The biodistribution and tumor localization data in vivo suggest that antibodies radiolabeled via their oligosaccharides might represent improved immunoscintigraphy reagents. It was then desirable to see whether 'In-labeled oligosaccharide-modified antibody conjugates would lead to the same extent of hepatic uptake reported by others for nonselective "'In conjugates (12, (15) (16) (17) (18) (19) Fig. 3D and the data in Table 2 The images from tumor-bearing animals obtained at various times after injection (Fig. 3 A-C) show that the 111In-labeled conjugate remains in the tumor over a period of several days. The localization within 24 hr is more rapid than the rates of uptake in several reports using intact antibody (44, 45) . The controls (Fig. 3 D and E) 
